Pharmacological parameters of intravenously administered amphotericin B in rats: Comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 1, 1999, Pages 77-84

  Souza, Liliete Canes ^a   Campa, Ana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; DRUG VEHICLE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG CLEARANCE; DRUG STABILITY; DRUG STORAGE; EMULSION; KIDNEY; LD 50; LETHALITY; LIVER; LUNG; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PLASMA CLEARANCE; RAT; SURVIVAL RATE; TISSUE DISTRIBUTION; TOXICITY;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; ERYTHROCYTES; FAT EMULSIONS, INTRAVENOUS; LETHAL DOSE 50; MALE; MICE; MICE, INBRED BALB C; POTASSIUM; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0032815841     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.1.77     Document Type: Article

References (45)

1. Khoo, S. H., Bond, J. & Denning, D. W. (1994). Administering amphotericin B - a practical approach. Journal of Antimicrobial Chemotherapy 33, 203-13.
2. Sarosi, G. A. (1990). Amphotericin B. Still the 'gold standard' for antifungal therapy. Postgraduate Medicine 88, 151-2, 155-61, 165-6.
3. Schmitt, H. J. (1993). New methods of delivery of amphotericin B. Clinical Infectious Diseases 17, Suppl. 2, S501-6.
4. Swerdloff, J. N., Filler, S. G. & Edwards, J. E. (1993). Severe candidal infections in neutropenic patients. Clinical Infectious Diseases 17, Suppl. 2, 457-67.
5. Lopez-Berestein, G., Bodey, G. P., Frankel, L. S. & Mehta, K. (1987). Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. Journal of Clinical Oncology 5, 310-17.
6. Brajtburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clinical Microbiology Reviews 9, 512-31.
7. Hay, R. J. (1994). Liposomal amphotericin B, AmBisome. Journal of Infection 28, Suppl. 1, 35-43.
8. Stevens, D. A. (1994). Overview of amphotericin B colloidal dispersion (Amphocil). Journal of Infection 28, Suppl. 1, 45-9.
9. Perfect, J. R. & Wright, K. A. (1994). Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. Journal of Antimicrobial Chemotherapy 33, 73-81.
10. Brajtburg, J., Elberg, S., Kobayashi, G. S. & Bolard, J. (1994). Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Antimicrobial Agents and Chemotherapy 38, 300-6.
11. Chavanet, P., Duong, M., Buisson, M., Hamel, H., Dubois, C., Bonnin, A. et al. (1997). In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits. Journal of Antimicrobial Chemotherapy 39, 427-30.
12. Davis, S. S., Washington, C., West, P., Illum, L., Liversidge, G., Sternson, L. et al. (1987). Lipid emulsions as drug delivery systems. Annals of the New York Academy of Sciences 507, 75-88.
13. Tabosa do Egito, E. S., Appel, M., Fessi, H., Barratt, G., Puisieux, F. & Devissaguet, J.-P. (1996). In-vitro and in-vivo evaluations of a new amphotericin B emulsion-based delivery system. Journal of Antimicrobial Chemotherapy 38, 485-97.
14. Souza, L. C., Maranhão, R. C., Schreier, S. & Campa, A. (1993). In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. Journal of Antimicrobial Chemotherapy 32, 123-32.
15. Marzzullo, L., Souza, L. C. & Campa, A. (1997). Effect of amphotericin B associated to lipid emulsion upon the oxidative burst of human polymorphonuclear leukocytes. General Pharmacology 28, 203-7.
16. Singleton, W. S., Gray, M. S., Brown, M. L. & White, J. L. (1965). Chromatographically homogeneous lecithin from egg phospholipids. Journal of the American Oil Chemists' Society 42, 53-6.
17. Kamp, H. H., Wirtz, W. A., Baer, P. R., Slotboom, A. J., Rosenthal, A. F., Paltauf, F. et al. (1977). Specificity of the phosphatidylcholine exchange protein from bovine liver. Biochemistry 16, 1310-16.
18. Redgrave, T. G. & Maranhão, R. C. (1985). Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochimica et Biophysica Acta 835, 104-12.
19. Reed, L. J. & Muench, H. (1938). A simple method of estimating fifty per cent endpoints. American Journal of Hygiene 27, 493-7.
20. Shihabi, Z. K., Wasilauskas, B. L. & Peacock, J. E. (1988). Serum amphotericin B assay by scanning spectrophotometer. Therapeutic Drug Monitoring 10, 486-9.
21. Neter, J., Wasserman, W. & Kutner, M. H. (1985). Interference in regression analysis. In Applied Linear Statistical Models, 2nd edn, pp. 60-108. Irwin, Homewood.
22. Winner, B. J. (1971), Multifactor experiments having repeated measures on the same elements. In Statistical Principles in Experimental Design, 2nd edn, pp. 514-603. McGraw-Hill, Kogakusha, Tokyo.
23. Lee, E. T. (1980). Nonparametric methods for comparing survival distributions. In Statistical Methods for Survival Data Analysis, pp. 122-56. Lifetime Learning Publications, Belmont, CA.
24. Kobayashi, Y. & Maudsley, D. V. (1974). Biological Applications of Liquid Scintillation Counting, pp. 51. Academic Press, New York.
25. 2. Journal of Free Radicals in Biology and Medicine 1, 43-9.
26. Proffitt, R. T., Satorius, A., Chiang, S. M., Sullivan, L. & Adler-Moore, J. P. (1991). Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 26, Suppl. B, 49-61.
27. Mitsutake, K., Kohno, S., Miyazako, Y., Noda, T., Miyazaki, H., Miyasaki, T. et al. (1994) In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex. Mycopathologica 128, 13-17.
28. Chavanet, P., Joly, V., Rigaud, D., Bolard, J., Carbon, C. & Yeni, P. (1994). Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrobial Agents and Chemotherapy 38, 963-8.
29. Marzzullo, L., Oliveira, E. P., Souza, L. C. & Campa, A. (1996). Toxicity of amphotericin B in analbuminemic rats. Environmental Toxicology and Pharmacology 2, 31-4.
30. Wasan, K. M., Vadiei, K., Lopez-Berestein, G. & Luke, D. R. (1990). Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. Journal of Infectious Diseases 161, 562-6.
31. Sacks, G. S. & Cleary, J. D. (1997). Nutritional impact of lipid-associated amphotericin B formulations. Annals of Pharmacotherapy 31, 121-2.
32. Joly, V., Farinotti, R., Saint-Julien, L., Chéron, M., Carbon, C. & Yeni, P. (1994). In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungi-zone) associated with Intralipid. Antimicrobial Agents and Chemotherapy 38, 177-83.
33. Kirsh, R., Goldstein, R., Tarloff, J., Parris, D., Hook, J., Hanna, N. et al. (1988). An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. Journal of Infectious Diseases 158, 1065-70.
34. Chavanet, P. Y., Garry, I., Charlier, N., Caillot, D., Kisterman, J. P., D'Athis, M. et al. (1992). Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. British Medical Journal 305, 921-5.
35. Caillot, D., Reny, G., Solary, E., Casasnovas, O., Chavanet, P., Bonnotte, B. et al. (1994). A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. Journal of Antimicrobial Chemotherapy 33, 603-13.
36. Heinemann, V., Kähny, B., Debus, A., Wachholz, K. & Jehn, N. (1994). Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid based formulations. Bone Marrow Transplantation 14, Suppl. 5, S8-9.
37. Collette, N., van der Auwera, P., Meunier, F., Lambert, C., Sculier, J. P. & Coune, A. (1991). Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. Journal of Antimicrobial Chemotherapy 21, 535-48.
38. Olsen, S. J., Swerdel, M. R., Blue, B., Clark, J. M. & Bonner, D. P. (1991). Tissue distribution of amphotericin B lipid complex in laboratory animals. Journal of Pharmacy and Pharmacology 43, 831-5.
39. Levine, S. J., Walsh, T. J., Martinez, A., Eichacker, P. Q., Lopez-Berestein, G. & Natanson, C. (1991). Cardiopulmonary toxicity after liposomal amphotericin B infusion. Annals of Internal Medicine 114, 664-6.
40. Clemons, K. V. & Stevens, D. A. (1993). Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. Journal of Antimicrobial Chemotherapy 32, 465-72.
41. Hopfer, R. L., Mills, K., Mehta, R., Lopez-Berestein, G., Fainstein, V. & Juliano, R. L. (1984). In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrobial Agents and Chemotherapy 25, 387-9.
42. Ralph, E. D., Khazindar, A. M., Barber, K. R. & Grant, C. W. M. (1991). Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrobial Agents and Chemotherapy 35, 188-91.
43. Pahls, S. & Schaffner, A. (1994). Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. Journal of Infectious Diseases 169, 1057-61.
44. Wasan, K. M. & Lopez-Berenstein, G. (1994). The interaction of liposomal amphotericin B and serum lipoproteins with the biological milieu. Journal of Drug Targeting 2, 373-80.
45. Verweij, P. E., Donnelly, J. P., Kullberg, B. J., Meis, J. F. G. M. & de Pauw, B. E. (1994). Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 22, 81-5.